Bone Grafts and Substitutes Global Market Report 2024

The bone grafts and substitutes market size has grown strongly in recent years. It will grow from $3.17 billion in 2023 to $3.37 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The historic growth can be linked to a surge in demand for orthopedic medical devices, higher rates of disabilities, increased instances of joint replacement surgeries, elevated healthcare spending, and robust economic development in emerging markets.

The bone grafts and substitutes market size is expected to see strong growth in the next few years. It will grow to $4.22 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. The forecasted growth is driven by an aging population, a rise in road accidents and sports-related injuries, growing demand for joint reconstruction treatments, and an increasing number of amputations due to diabetes. Key trends in this period involve new product introductions, the emergence of 3D-printed bone grafts, and an emphasis on partnerships and collaborations.

The increasing prevalence of musculoskeletal disorders, including conditions such as osteoporosis and tendonitis, is anticipated to drive the growth of the bone grafts and substitutes market. Musculoskeletal disorders encompass a range of injuries and conditions affecting the body's movement and musculoskeletal system, impacting muscles, nerves, tendons, joints, cartilage, and spinal discs. This surge in musculoskeletal disorders has led to a heightened demand for bone grafts and substitutes. Notably, in March 2022, a Pediatric Orthopedic Consultant at the Indian Spinal Injuries Centre in Delhi reported a significant 50% increase in Pediatric Orthopaedic Cases, attributing this rise to poor posture among students during online classes. Consequently, the escalating incidence of musculoskeletal disorders is expected to contribute to the growing demand for products in the bone grafts and substitutes market.

The continuous rise in road accidents and sports injuries is poised to be a significant driver for the bone grafts and substitutes market. Factors such as speeding, lack of safety gear usage, increased vehicle numbers, inadequate road infrastructure, growing sports activities, the inherent risk in sports, and other contributing factors have led to a surge in road accidents and sports injuries. These incidents often result in fractures and disabilities that necessitate the use of bone grafts and substitutes for effective treatment. As an illustration, the projected number of road accidents per one million inhabitants in the United States is expected to surpass 7,100 by 2025. Consequently, the increasing prevalence of road accidents and sports injuries is expected to be a key factor propelling the growth of the bone grafts and substitutes market.

The bone grafts and substitutes market is witnessing a prominent trend characterized by new product innovations. Leading companies in this market are strategically directing their efforts towards innovating products to align with evolving consumer demands. A noteworthy example is Orthofix, a prominent US-based bone graft device manufacturer, which introduced the Orthofix fiberFUSE Strip in July 2021. This advanced demineralized bone graft solution, incorporating cancellous bone, offers a sophisticated option for various applications, including posterior cervical, posterior lumbar, and degenerative spinal surgery prevention. The fiberFUSE Strip is crafted with mineralized cancellous and demineralized cortical bone fibers, contributing to the bone healing process.

Partnerships and collaborations have become a focal point for companies operating in the bone grafts and substitutes market as they seek to enhance their product portfolios and extend their geographical presence. An illustrative case is the acquisition undertaken by Dentsply Sirona, a leading US-based dental equipment manufacturer, in January 2021. Dentsply Sirona acquired Datum Dental Ltd., an Israeli company specializing in clinically superior patented dental regeneration solutions. This strategic move bolsters Dentsply Sirona's existing implant dentistry strategy, emphasizing brands such as Ankylos, Astra Tech Implant System, Xive, and Atlantis. The focus is on ensuring proven quality and relevant innovation in line with evolving market needs.

In March 2021, Bioventus, a US-based company specializing in innovative healing solutions, completed the acquisition of Bioness Inc. for an initial consideration of $45 million, with a potential additional $65 million upon meeting specified milestones. This acquisition grants Bioventus access to Bioness's full product portfolio and ongoing research and development initiatives, specifically targeting bone healing and osteoarthritis treatment. Bioness Inc., based in Spain, is known for its minimally invasive trauma treatments, solutions for managing osteoarthritis-related joint pain, and bone graft substitutes.

Major companies operating in the bone grafts and substitutes market report are Medtronic PLC, Stryker Corporation, Smith & Nephew, Johnson & Johnson, Zimmer Biomet, Baxter International Inc., SeaSpine, Integra Lifesciences Holdings Corporation, NuVasive Inc., Orthofix Holdings Inc., Bioconcept Dental Implants, NovaBone India, Straumann, Kamal Medtech, Geistlich Bio-Oss, Lindare Medical, Hospital Innovations, Bioimplon, Exabone GmbH, Mathys AG, Dentsply Sirona Inc., Danaher Corp, Arthrex Inc., Graftys, Osseocon Biomateriais, Einco Biomaterial, Bionnovation, Medbone Biomaterials, CoreBone, Datum Dental, OK Coral, Dentakay Dental Clinic, Turkeyana Clinic, Keystone Dental, Allosource, DePuy Synthes, Wright Medical Group N.V.

North America was the largest region in the bone grafts and substitutes market in 2023. The regions covered in the bone grafts and substitutes market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the bone grafts and substitutes market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary types of bone grafts and substitutes include allografts, synthetics, and xenografts. Allografts involve tissue donation from the same species as the recipient and are frequently used in spinal fusion surgeries. These procedures find applications in spinal fusion, trauma, craniomaxillofacial, joint reconstruction, dental bone grafting, and are utilized across various medical settings such as hospitals and surgical centers.

The bone grafts and substitutes market research report is one of a series of new reports that provides bone grafts and substitutes market statistics, including bone grafts and substitutes industry global market size, regional shares, competitors with a bone grafts and substitutes market share, detailed bone grafts and substitutes market segments, market trends and opportunities, and any further data you may need to thrive in the bone grafts and substitutes industry. This bone grafts and substitutes market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

The bone grafts and substitutes market consists of sales of xenograft tissue, alloplast bone graft, autograft tissue, and allograft tissue. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.